B. Devens

发表

11 – An Isoform-selective Inhibitor of Cyclic AMP-Specific Phosphodiesterase (PDE4) with Anti-inflammatory Properties

M. Conti, R. Alvarez, D. V. Daniels, 1996 .

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

Sean C. Bendall, Michael N. Alonso, J. Melrose, 2020, Nature Cancer.

Transduction of the IFN-gamma signal for HLA-DR expression in the promonocytic line THP-1 involves a late-acting PKC activity.

B. Devens, D. Webb, J. Freire-Moar, 1991, Cellular immunology.

Influence of dietary restriction and aging on natural killer cell activity in mice.

R. Weindruch, B. Devens, R. Walford, 1983, Journal of immunology.

A Pilot Trial Targeting the ICOS–ICOS‐L Pathway in Nonhuman Primate Kidney Transplantation

A. Kirk, B. Devens, M. Song, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

The design and synthesis of a nonpeptide mimic of an immunosuppressing peptide

B. Devens, M. Kahn, 1986 .

Immunosuppressive effect of ASP2408, a novel CD86-selective variant of CTLA4-Ig, in rats and cynomolgus monkeys.

B. Devens, F. Takamura, H. Mizuhara, 2016, International immunopharmacology.

Involvement of two distinct regulatory T cell populations in the antigen-specific suppression of cytolytic T cell generation.

B. Devens, D. Webb, J. Kapp, 1991, Journal of immunology.

Rapid in vitro screening assay for immunotoxic effects of organophosphorus and carbamate insecticides on the generation of cytotoxic T-lymphocyte responses

B. Devens, K. Rodgers, T. Imamura, 1986 .

Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase by nuclear variants of mycophenolic acid.

R. C. Hawley, B. Devens, C. González, 1996, Journal of medicinal chemistry.

21 – Immunotoxic effects of anticholinesterases

B. Devens, K. Rodgers, T. Imamura, 1992 .

Investigations into the mechanism of immunosuppression caused by acute treatment with O,O,S-trimethyl phosphorothioate. II. Effect on the ability of murine macrophages to present antigen.

B. Devens, K. Rodgers, T. Imamura, 1985, Immunopharmacology.

Investigations into the mechanism of immunosuppression caused by acute treatment with O,O,S-trimethyl phosphorothioate: generation of suppressive macrophages from treated animals.

B. Devens, K. Rodgers, T. Imamura, 1987, Toxicology and applied pharmacology.

Production of human-human hybridomas secreting antibody to sheep erythrocytes after in vitro immunization.

R. Lundak, B. Devens, L. Strike, 1984, Journal of immunology.

More speculations on specific suppression.

B. Devens, D. Webb, J. Kapp, 1989, Immunology today.

O,O,S-Trimethyl phosphorothioate effects on immunocompetence

B. Devens, K. Rodgers, T. Imamura, 1985 .

Organophosphorus pesticide immunotoxicity: effects of O,O,S-trimethyl phosphorothioate on cellular and humoral immune response systems.

B. Devens, K. Rodgers, T. Imamura, 1986, Immunopharmacology.

Investigations into the mechanism of immunosuppression caused by acute treatment with O,O,S-trimethyl phosphorothioate. I. Characterization of the immune cell population affected.

B. Devens, K. Rodgers, T. Imamura, 1985, Immunopharmacology.

Effects of subchronic treatment with O,O,S-trimethyl phosphorothioate on cellular and humoral immune response systems.

B. Devens, K. Rodgers, T. Imamura, 1985, Toxicology and applied pharmacology.

In vitro effects of malathion and O,O,S-trimethyl phosphorothioate on cytotoxic T-lymphocyte responses

B. Devens, K. Rodgers, M. Grayson, 1985 .

Induction of apoptosis by aryl-substituted diamines: role of aromatic group substituents and distance between nitrogens.

M. McVean, B. Devens, G. F. Graminski, 2002, Bioorganic & medicinal chemistry letters.

Drug metabolizing capabilities and drug-induced immunosuppression in two strains of H-2 congenic mice

R. Weindruch, B. Devens, R. Walford, 1984, AGE.

Evidence for a calcium regulated, bidirectional intronic promoter in the murine TCR Vα1 gene

C. Turck, B. Devens, D. Webb, 1995 .

Anti-DNA antibody: avidity and valence measurements, studies using sera from immunized rabbits and from two systemic lupus erythematosus patients.

B. Devens, E. Barnett, D. Chia, 1978, Journal of immunological methods.

Lack of immunosuppressive effects of acute and subacute administration of malathion on murine cellular and humoral immune responses

C. Ware, B. Devens, K. Rodgers, 1986 .

Induction of murine fibrosarcomas by low dose treatment with 3-methylcholanthrene followed by promotion with 12-O-tetradecanoyl-phorbol-13-acetate.

C. Byus, R. Lundak, B. Devens, 1984, Cancer letters.

The Effect of ASP2409, a Novel CD86-Selective Variant of CTLA4-Ig, on Renal Allograft Rejection in Nonhuman Primates

B. Devens, S. Tsujimoto, J. Hirose, 2016, Transplantation.

ASP2408 and ASP2409, novel CTLA4-Ig variants with CD86-selective ligand binding activity and improved immunosuppressive potency, created by directed evolution.

S. Bass, M. Whitlow, Qian Zhang, 2016, Protein engineering, design & selection : PEDS.

A 69-kDa membrane protein associated with lipopolysaccharide (LPS)-induced signal transduction in the human monocytic cell line THP-1.

B. Devens, D. Webb, T. Maeda, 1995, Cellular immunology.

Antipeptide antibody specific for the N-terminal of soluble immune response suppressor neutralizes concanavalin A and IFN-induced suppressor cell activity in an in vitro cytotoxic T lymphocyte response.

B. Devens, D. Webb, G. Semenuk, 1988, Journal of immunology.